课题基金 / 基金详情

Acquisition of a Next Generation Orbitrap MS

Acquisition of a Next Generation Orbitrap MS
获得下一代 Orbitrap MS
批准号:
8640367
负责人:
Michael A. Freitas
金额:
$57.25万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-07-15 至 2015-07-14

项目摘要

项目成果

Michael A. Freitas的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): In this application we are requesting funds for the purchase of a ThermoScientific a next-generation Q-LTQ Orbitrap. We are requesting this instrument because its capabilities are well suited for bottom-up, middle-down and top-down protein characterization, high-sensitivity quantitative proteomics of limited samples and post- translational modification analysis. The requested next-generation hybrid Orbitrap has several key improvements over the current LTQ Orbitrap Elite that allow it to achieve better performance: 1) Mass selecting quadrupole available to select ions for Orbitrap or ion trap analysis, 2) Parallel operation of both ion trap and Orbitrap mass analyzers allowing for significantly increased scan rate, 3) HCD cell for ion accumulation in single ion or multiplexed modes, 4) Full flexibility of CID, HCD and ETD dissociations at any stage of MSn analysis, 5) Ultrahigh field Orbitrap with advanced transient processing, 6) Novel, high performance front-end ETD source and dedicated internal mass calibration. These improvements along with reduced overhead result in a high-resolution data acquisition rate greater than other designs without sacrificing sensitivity or dynamic range. The faster combined MS1 and MS2 scan rates of the requested next-gen Orbitrap are essential for LC- MS/MS with high efficiency ultra-high pressure LC separations, resulting in reduced proteomic experiment time without loss of data quality. This requested next-generation Q-LTQ Orbitrap will be critical to support the needs of several Major Users that performing large-scale proteomics on human tissue where samples are limited and sensitivity and throughput are key requirements.
期刊论文(9)
专著(0)
科研奖励(0)
会议论文
Concurrent renal amyloidosis and thymoma resulting in a fatal ventricular thrombus in a dog.
并发肾淀粉样变性和胸腺瘤导致狗致命的心室血栓。
DOI: 10.1111/jvim.15062
发表时间: 2018
期刊: Journal of veterinary internal medicine
影响因子: 2.6
作者: [Loewen,JenniferM, Cianciolo,RachelE, Zhang,Liwen, Yaeger,Michael, Ward,JessicaL, Smith,JodiD, LeVine,DanaN]
通讯作者: LeVine,DanaN
DOI: 10.1002/pmic.201700442
发表时间: 2018-06
期刊: Proteomics
影响因子: 3.4
作者: [Jiang T, Hoover ME, Holt MV, Freitas MA, Marshall AG, Young NL]
通讯作者: Young NL
DOI: 10.1016/j.mcpro.2022.100256
发表时间: 2022-07
期刊: MOLECULAR & CELLULAR PROTEOMICS
影响因子: 7
作者: [Johnson, Benjamin S., Chafin, Lexie, Farkas, Daniela, Adair, Jessica, Elhance, Ajit, Farkas, Laszlo, Bednash, Joseph S., Londino, James D.]
通讯作者: Londino, James D.
DOI: 10.1016/j.jbc.2021.101327
发表时间: 2021-11
期刊: The Journal of biological chemistry
影响因子: --
作者: [Ellenbogen JB, Jiang R, Kountz DJ, Zhang L, Krzycki JA]
通讯作者: Krzycki JA
Identification of Histone Modification Interaction Networks
  • 批准号:
    7570472
  • 项目类别:
  • 资助金额:
    $26.25万
  • 财政年份:
    2009
  • 负责人:
    Michael A. Freitas
  • 依托单位:
Identification of Histone Modification Interaction Networks
  • 批准号:
    7897917
  • 项目类别:
  • 资助金额:
    $26.25万
  • 财政年份:
    2009
  • 负责人:
    Michael A. Freitas
  • 依托单位:
Acquisition of a high-throughput high mass accuracy MS for chromatin research
  • 批准号:
    7215080
  • 项目类别:
  • 资助金额:
    $50.0万
  • 财政年份:
    2007
  • 负责人:
    Michael A. Freitas
  • 依托单位:
Assays for Screening Histone Modification in Cancer
  • 批准号:
    6941103
  • 项目类别:
  • 资助金额:
    $23.55万
  • 财政年份:
    2004
  • 负责人:
    Michael A. Freitas
  • 依托单位:
国内基金
海外基金
分化肌细胞脱细胞ECM-cells sheet 3D 支架构建及其促进容积性肌组织缺损再 生修复应用及机制研究
CAFs-TAMs-tumor cells调控在HRHPV感染致癌中的作用机制研究及AI可追溯预测模型建立
  • 批准号:
    82072862
  • 项目类别:
    面上项目
  • 资助金额:
    56.0万元
  • 批准年份:
    2020
  • 负责人:
    徐云升
  • 依托单位:
S100A8/A9--Myeloid cells特异性可溶性表氧化物水解酶(sEH)基因敲除改善胰岛素抵抗的新靶点
  • 批准号:
    82070825
  • 项目类别:
    面上项目
  • 资助金额:
    53.0万元
  • 批准年份:
    2020
  • 负责人:
    徐西振
  • 依托单位:
Leader cells通过CCL5调控糖酵解及基质硬度促进结直肠癌集体侵袭的 作用机制
  • 批准号:
    81903002
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.5万元
  • 批准年份:
    2019
  • 负责人:
    王斐斐
  • 依托单位: